Clinical Trial Detail

NCT ID NCT02248090
Title AZD9496 First Time in Patients Ascending Dose Study
Recruitment Active, not recruiting
Gender female
Phase Phase I
Variant Requirements yes
Sponsors AstraZeneca
Indications

Her2-receptor negative breast cancer

Therapies

AZD9496

Age Groups: adult

Additional content available in CKB BOOST